(poe TASS ee um pe a mee noe BEN zoe ate)
- Aminobenzoate Potassium
- Potassium Aminobenzoate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
M2 Potassium: 60 mg [DSC]
Potaba: 500 mg
Generic: 2 g (50 ea)
Potaba: 500 mg [DSC]
Brand Names: U.S.
- M2 Potassium [OTC] [DSC]
- Vitamin, Water Soluble
P-aminobenzoate is a member of the vitamin B complex family. It may have an antifibrotic effect due to increased oxygen uptake at the tissue level.
Use: Labeled Indications
Presently, all indications are classified by the FDA as “possibly effective.”
Treatment of scleroderma, dermatomyositis, morphea, linear scleroderma, pemphigus, Peyronie's disease
Hypersensitivity to potassium p-aminobenzoate or any component of the formulation; concurrent use of sulfonamides
Oral: Average dose: 12 g/day in 4-6 divided doses
Refer to adult dosing.
Oral: 1 g/10 pounds of weight/day; administer in divided doses
Dosing: Renal Impairment
No dosage adjustment provided in manufacturer’s labeling. Use with caution.
Dosing: Hepatic Impairment
No dosage adjustment provided in manufacturer’s labeling.
All forms should be administered after meals or with a snack.
Capsule: Take with a glass of water.
Tablet: Crush and add to glass of chilled water or juice; stir and drink.
Take with food to avoid stomach upset.
Sulfonamide Derivatives: Potassium P-Aminobenzoate may diminish the therapeutic effect of Sulfonamide Derivatives. Avoid combination
Frequency not defined.
Central nervous system: Fever
Gastrointestinal: Anorexia, nausea
Miscellaneous: Hypersensitivity reaction
Concerns related to adverse effects:
• Anorexia: Interrupt therapy if anorexia occurs; may reinstitute once patient improves.
• Nausea: Interrupt therapy if nausea occurs; may reinstitute once patient improves.
• Diabetes: Use with caution in patients with diabetes mellitus or a history of hypoglycemia.
• Renal impairment: Use with caution in patients with renal impairment.
Safety for use in pregnancy has not been established.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Have patient report immediately to prescriber lack of appetite or nausea (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.